Press Release: Fierce Biotech : Fierce Biotech Names ILiAD Biotechnologies to its 2024 Fierce 15

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a biotech company developing the most advanced next generation pertussis vaccine (BPZE1), announced today that Fierce Biotech has named the Company to the Fierce 15 2024 list (link), identifying ILiAD as one of the most promising and innovative biotechnology companies in the industry. ILiAD's BPZE1 intranasal pertussis vaccine has been studied in four Phase 2 clinical trials in adults and school age children and has demonstrated